Courtagen, Astellas Collaborate
News Sep 19, 2016
Courtagen enters data partnership with Astellas for early stage therapeutic development program to address mitochondrial disease.
Courtagen Life Sciences, Inc. announced collaboration with Astellas Pharma Inc. Courtagen will utilize its molecular information platform to aid in the development of a predictive model to support early stage therapeutic development for mitochondrial disease.
“Astellas and Courtagen share a commitment to innovative clinical solutions that address the needs of patients suffering from mitochondrial based disorders.” states Brian McKernan, Chief Executive Officer of Courtagen. “Courtagen was founded on the idea of helping patients suffering from mitochondrial disorders, and now we are able to utilize our unique capability to correlate clinical data with specific genomic alterations and aid in the development of targeted therapeutics.”
ExPecto Patronum! Magical Machine Learning Tool Summons DNA Dark Matter DataNews
A new machine learning framework, dubbed ExPecto, can predict the effects of mutations in the so-called “dark matter” regions of the human genome. ExPecto pinpoints how mutations can disrupt the way genes turn on and off throughout your body.
3D Super-Resolution Nanoscopes Used To Identify Amyloid PlaquesNews
A new development in 3D super-resolution imaging gives insight on Alzheimer's diseaseREAD MORE
Sex Differences Revealed: Heart Failure Death RatesNews
Death from heart failure in men and women compared in a study of over 90 000 patientsREAD MORE